Atlas Venture, a leading biotech investment firm, secured $400 million for its third Opportunity Fund aimed at financing growth-stage companies within its portfolio. This strategic fund targets young biotech startups facing funding challenges in a subdued investment climate, providing them with essential resources to advance drug development. The new fund reflects Atlas’ refined approach to raising capital tailored to its seed-led venture creation strategy. The firm’s portfolio boasts successes like Alnylam Pharmaceuticals and recent spinouts poised for growth. Atlas aims to maintain discipline and focus after prior rapid expansions, supporting innovation through patient capital amid current industry headwinds.